Calamos Advisors’s HCA Healthcare HCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.1M | Buy |
48,868
+495
| +1% | +$249K | 0.08% | 252 |
|
|
2025
Q4 | $22.6M | Sell |
48,373
-1,964
| -4% | -$912K | 0.08% | 242 |
|
|
2025
Q3 | $21.5M | Hold |
50,337
| – | – | 0.08% | 267 |
|
|
2025
Q2 | $19.3M | Hold |
50,337
| – | – | 0.08% | 276 |
|
|
2025
Q1 | $17.4M | Buy |
50,337
+561
| +1% | +$180K | 0.08% | 281 |
|
|
2024
Q4 | $14.9M | Sell |
49,776
-85
| -0.2% | -$29.7K | 0.06% | 318 |
|
|
2024
Q3 | $20.3M | Sell |
49,861
-1,136
| -2% | -$416K | 0.09% | 269 |
|
|
2024
Q2 | $16.4M | Sell |
50,997
-1,861
| -4% | -$605K | 0.07% | 287 |
|
|
2024
Q1 | $17.6M | Sell |
52,858
-1,329
| -2% | -$406K | 0.08% | 274 |
|
|
2023
Q4 | $14.7M | Sell |
54,187
-708
| -1% | -$175K | 0.07% | 310 |
|
|
2023
Q3 | $13.5M | Hold |
54,895
| – | – | 0.07% | 323 |
|
|
2023
Q2 | $16.7M | Hold |
54,895
| – | – | 0.08% | 299 |
|
|
2023
Q1 | $14.5M | Sell |
54,895
-6,863
| -11% | -$1.74M | 0.07% | 336 |
|
|
2022
Q4 | $14.8M | Sell |
61,758
-10,920
| -15% | -$2.45M | 0.07% | 337 |
|
|
2022
Q3 | $13.4M | Hold |
72,678
| – | – | 0.06% | 371 |
|
|
2022
Q2 | $12.2M | Buy |
72,678
+1,914
| +3% | +$411K | 0.05% | 430 |
|
|
2022
Q1 | $17.7M | Buy |
70,764
+9,469
| +15% | +$2.38M | 0.07% | 326 |
|
|
2021
Q4 | $15.7M | Buy |
61,295
+2,373
| +4% | +$581K | 0.06% | 341 |
|
|
2021
Q3 | $14.3M | Buy |
58,922
+5,200
| +10% | +$1.27M | 0.06% | 325 |
|
|
2021
Q2 | $11.1M | Buy |
53,722
+12,219
| +29% | +$2.49M | 0.05% | 373 |
|
|
2021
Q1 | $7.82M | Buy |
41,503
+1,283
| +3% | +$226K | 0.04% | 395 |
|
|
2020
Q4 | $6.62M | Sell |
40,220
-1,742
| -4% | -$255K | 0.04% | 427 |
|
|
2020
Q3 | $5.23M | Sell |
41,962
-53,683
| -56% | -$6.64M | 0.03% | 452 |
|
|
2020
Q2 | $9.28M | Buy |
95,645
+47,080
| +97% | +$4.89M | 0.07% | 312 |
|
|
2020
Q1 | $4.36M | Sell |
48,565
-4,070
| -8% | -$527K | 0.03% | 423 |
|
|
2019
Q4 | $7.78M | Sell |
52,635
-867
| -2% | -$116K | 0.04% | 414 |
|
|
2019
Q3 | $6.44M | Sell |
53,502
-2,287
| -4% | -$296K | 0.04% | 453 |
|
|
2019
Q2 | $7.54M | Buy |
55,789
+7,832
| +16% | +$990K | 0.04% | 412 |
|
|
2019
Q1 | $6.25M | Buy |
47,957
+466
| +1% | +$62.6K | 0.04% | 414 |
|
|
2018
Q4 | $5.91M | Buy |
47,491
+8,312
| +21% | +$1.12M | 0.04% | 405 |
|
|
2018
Q3 | $5.45M | Buy |
+39,179
| New | +$4.88M | 0.03% | 445 |
|
|
2017
Q3 | – | Sell |
-146,641
| Closed | -$12.8M | – | 633 |
|
|
2017
Q2 | $12.8M | Sell |
146,641
-4,511
| -3% | -$382K | 0.09% | 252 |
|
|
2017
Q1 | $13.5M | Sell |
151,152
-8,387
| -5% | -$699K | 0.11% | 249 |
|
|
2016
Q4 | $11.8M | Buy |
+159,539
| New | +$11.9M | 0.09% | 241 |
|
|
2016
Q2 | – | Sell |
-842,731
| Closed | -$65.8M | – | 626 |
|
|
2016
Q1 | $65.8M | Buy |
842,731
+10,661
| +1% | +$744K | 0.44% | 61 |
|
|
2015
Q4 | $56.3M | Buy |
832,070
+85,772
| +11% | +$5.98M | 0.36% | 81 |
|
|
2015
Q3 | $57.7M | Buy |
+746,298
| New | +$66.1M | 0.4% | 74 |
|
Other funds holding HCA
VCM
VPM
Calamos Advisors's HCA Position: Q1 2026 in Review
Calamos Advisors increased its HCA Healthcare (HCA) stake by 1% in Q1 2026, buying an estimated $249K and bringing the position to 48,868 shares worth $23.1M. The position accounts for 0.08% of the portfolio, ranked #252.
Calamos Advisors first reported a position in HCA in Q3 2015 and has held it in 37 quarters since. The position peaked at $65.8M in Q1 2016. 1,414 funds tracked by Wall St. Rank hold HCA as of Q1 2026.
- Calamos Advisors held 48,868 shares of HCA Healthcare worth $23.1M as of Q1 2026.
- Calamos Advisors bought 495 HCA Healthcare shares in Q1 2026, an estimated $249K.
- HCA Healthcare made up 0.08% of Calamos Advisors's portfolio in Q1 2026, its #252 holding.
- Calamos Advisors first reported a position in HCA Healthcare in Q3 2015 and has held it in 37 quarters since.
- Calamos Advisors's HCA Healthcare position peaked at $65.8M in Q1 2016.
- 1,414 funds tracked by Wall St. Rank held HCA Healthcare as of Q1 2026.
Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.